Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients66

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients30

Views

Views
May 20250
June 20250
July 202518
August 20250
September 20253
October 20253
November 20256
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil14
United States6
Ecuador2
Chile1
Spain1
Ethiopia1
United Kingdom1
Honduras1
Kenya1
Senegal1
 

Top cities views

Views
Dallas2
Anápolis1
Arujá1
Awasa1
Brasília1
Campinas1
Carangola1
Casimiro de Abreu1
Cuenca1
Dakar1